U.S. markets closed

Pacira BioSciences, Inc. (PCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
61.25+0.81 (+1.34%)
At close: 4:00PM EST

61.25 0.00 (0.00%)
After hours: 4:30PM EST

Sign in to post a message.
  • Y
    Yahoo Finance Insights
    Pacira BioSciences reached a 52 Week high at 68.07
  • A
    Ashok
    What's going on with this stock today? Something to worry?
  • D
    David
    Hello Martin and other docs -- Please, do you have any experience with HTX-011? What is your view? Is the HTX-011 clearly better if it is approved? Heron's Jeffries analyst said that Exparel requires 50 needle sticks -- is that true? And that HTX-011 requires none? Any insights are appreciated!
  • M
    Martin
    Interventional pain doctor chiming in here… Exparel will now have countless opportunities in the Anesthesia/Pain Management space. Expect to see this drug used during epidural steroid injection, medial branch block, sacroiliac injection, and many more applications. I have been extremely impressed while utilizing this drug during sympathetic nerve blockade for complex regional pain syndrome.
    Probably the most common accepted utilization would be for medial branch nerve blockade, a procedure used to diagnose facet joint syndrome for neck or back pain. Traditional bupivacaine may only work in this area for a few hours. Many patients undergoing these procedures are sedated and thus have poor recollection of post-procedural success. Giving them 2 1/2 days of pain relief versus a few hours of relief is game changing… and leads to better, more advanced treatment with far less use of opiates! We have been inundated with problems associated with opiates, their addiction potential, and abuse potential.
    I'll leave you with another fun. Medial branch blockade, epidural steroid injection, and sacroiliac joint Injection often make up three of the top 10 most commonly performed/billed procedures in US ambulatory surgical centers. That is a lot of procedures…
  • d
    dukeandduke
    good earnings and you get a 1/2 percent price increase.
    something is not right here
  • J
    Justin
    Anesthesiologist here - started using Exparel for interscalene blocks this week. Amazing. We're changing from catheters in all of our shoulders to single shot blocks. Even at $133 per vial for Exparel it's a fraction of the cost of doing catheters and takes a fraction of the time to do them. Added benefit of needing a less experienced tech to assist with a single shot Exparel block over catheter placement and this is a no-brainer. Have already requested doubling our stock of Exparel on hand.
  • d
    dukeandduke
    Earnings will be great. We have rapidly accepted Exparel for IS with excellent results. Over 36 hours good pain control, some more. Orthopods happy about not getting that call for pain meds in the middle of the night.
  • M
    M
    Stranger things on Thursday: EXEL beat the estimate and keeps the year forecast and has $1B (yes with B) cash, positive cash flow and growing sales year over year then the stock goes down early but comes back some later in the day. PCRX comes below the estimate, struggles a bit but then takes off. Anyone knows why?
  • d
    dukeandduke
    We like our pain docs to use this in adductor canal after ACL. Another indication. Off label but eventually to be accepted
  • A
    Ashok
    Is $34 a buy now? When is the $50 target timeline?
  • r
    rachid
    $BXRX conversation
    For comparison: $PCRX which bread-winner is EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements, has revenues of about $400M. It trades at 4 times revenue.

    If as analysts predicts, $BXRX reaches peak revenue of $350M, if you apply an even lower multiple, say 2.5, you'd get to a $875M market cap. If fully diluted we end up with 25M shares --> you'd get at a share price of: 35$ !!!!!!

    If Peak sales are overestimated and we just get half of it, PPS should still be, if you follow $PCRX metric at $17!!!!

    THAT IS A 630% GAIN FROM TODAY'S PRICE!!!!!!!!!!!!!!!

    And people still sell this stock! smh.
  • g
    grntip
    Watch out for HTX011 from Heron. (HRTX) Their product is much better than your Exparel in many ways. Anybody with PCRX stock better know this and do some research in a hurry. Heron is due to get FDA approval on HTX011 by April 30th 2019 as the FDA has just granted them Priority review. HTX011 will steal away vast amounts of your Exparel market share. You May want to jump ship to Heron ASAP. Having read this, what ever you do will be on YOU. Good Luck
  • m
    michael
    Why so many pcrx haters on this page? Pcrx has been used in millions of surgeries without any problems. They have studies with knees, shoulder, hips, hernias, C-sections, and breast reductions. Only successful study I’ve seen from hrtx is bunion surgery. Let us longs enjoy our day with nice gain from hrtx loss, remember not to long ago when the same thing happen to pcrx holders. PCRX holders good luck with earnings.
  • m
    mike
    HTRX much better and approval coming Tuesday if buyers are bitting that HRTX won't be approved they may be in trouble here.
  • m
    michael
    I live in Brunswick county NC, 30 miles away from Wilmington NC one of the most opioid addictive locations in the country. I am scheduled to have shoulder procedure and was told that Exparel was more effective and preferred by my surgeon but was too expensive. Are they really serious about easing the opioid epidemic?
  • L
    Leash
    Conference call was terrific. Met profit, beat revenue and will revise guidance when they get some indication of how much the expanded label will contribute. Everyone on the call was pretty upbeat. Conferences over the next couple of weeks should add some more knowledge to things they are working on with the FDA. Very solid outlook.
  • S
    Stephan
    When is this going to trade again?
  • d
    dukeandduke
    PCRX should recover
    Exparel in Interscalene, should be able to use in supraclavs & adductor canal amongst other blocks
    Heron still has p3, will be a competitor but meloxicam hasn't been studied in pnb
    Room for both. Who cuts the better deal?
  • L
    Les
    I love Exparel, using it daily for IS blocks. It has essentially replaced IS catheters. I’ve owned the stock for years and finally sold it about a year ago because I grew weary of lack of ROI. So disappointing. Only a couple of years remaining on patent. Don’t know if anyone can or will make a generic. If so, I and others will use instead. $170 for 10 ml is a hefty price to pay. I use more Exparel now than ever before. Great product, just doesn’t make enough money. Defies logic.
  • Y
    Yahoo Finance Insights
    PCRX is down -7.61% to 28.55